Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-dfsvx Total loading time: 0 Render date: 2024-04-29T19:41:00.929Z Has data issue: false hasContentIssue false

Chap. 17 - SEVERE, ACUTE COMPLICATIONS OF DERMATOLOGIC THERAPIES

Published online by Cambridge University Press:  07 September 2011

Ronni Wolf
Affiliation:
Hebrew University–Hadassah Medical School
Jasna Lipozenčić
Affiliation:
University of Zagreb
Batya B. Davidovici
Affiliation:
Kaplan Medical Center
Ronni Wolf
Affiliation:
Kaplan Medical Center, Rehovot, Israel
Batya B. Davidovici
Affiliation:
Kaplan Medical Center, Rehovot, Israel
Jennifer L. Parish
Affiliation:
Jefferson Medical College of Thomas Jefferson University
Lawrence Charles Parish
Affiliation:
Jefferson Medical College of Thomas Jefferson University
Get access

Summary

ALTHOUGH PHYSICIANS from other specialties, like the population at large, still consider cutaneous maladies as being mainly aesthetic, skin deep, and insignificant, they are generally aware that treating these diseases often requires a variety of potent systemic drugs and not only topical treatments. These powerful medications may cause many adverse reactions, some of them severe, acute, or even life threatening.

There are no really ‘safe’ biologically active drugs. There are only ‘safe’ physicians.” A “safe” physician must, first and foremost, be well informed about adverse reactions at the time of prescribing a drug, during the follow-up period, and especially when one of these rare catastrophes suddenly occurs. Because the diversity of severe adverse reactions to dermatologic therapies is almost endless, we focus on new drugs and the less known adverse effects.

TARGETED IMMUNE MODULATORS/BIOLOGICS

Targeted immune modulators (TIMs) – commonly referred to as biological response modifiers or simply “biologics” – are a relatively new category of medications used in the treatment of certain types of immunologic and inflammatory diseases, including dermatologic diseases, most notably psoriasis.

Overall, TIMs appear to have a good tolerability profile, although some rare but acute serious adverse events, such as infections, hematologic events, neurologic events, infusion reactions, congestive heart failure, nephrotic syndrome, and others, are of concern. The following sections describe adverse events associated with TIMs.

Type
Chapter
Information
Emergency Dermatology , pp. 168 - 177
Publisher: Cambridge University Press
Print publication year: 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kaminetzky, HA. A drug on the market. Obstet Gynecol. 1963; 21:512–13.Google Scholar
Kapetanovic, MC, Larsson, L, Truedsson, L, et al. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther. 2006; 8:R131.CrossRefGoogle ScholarPubMed
Cheifetz, A, Smedley, M, Martin, S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003; 98:1315–24.CrossRefGoogle ScholarPubMed
Cheifetz, A, Mayer, L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005; 72:250–6.Google ScholarPubMed
US Food and Drug Administration Arthritis Advisory Committee. Briefing information from the March 4, 2003 meeting of Arthritis Advisory Committee. 3 April 2007. Available from: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930b1.htm.
Keane, J, Gershon, S, Wise, RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345:1098–104.CrossRefGoogle ScholarPubMed
Gomez-Reino, JJ, Carmona, L, Valverde, VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003; 48:2122–7.CrossRefGoogle ScholarPubMed
Doherty, SD, Van, VA, Lebwohl, MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008; 59:209–17.CrossRefGoogle ScholarPubMed
Stas, P, D'Hoore, A, Van, AG, et al. Miliary tuberculosis following infliximab therapy for Crohn disease: a case report and review of the literature. Acta Gastroenterol Belg. 2006; 69:217–20.Google ScholarPubMed
Paimela, L, Johansson-Stephansson, EA, Koskimies, S, Leirisalo-Repo, M. Depressed cutaneous cell-mediated immunity in early rheumatoid arthritis. Clin Exp Rheumatol. 1990; 8:433–7.Google ScholarPubMed
Taylor, JC, Orkin, R, Lanham, J. Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy. Rheumatology (Oxford). 2003; 42:901–2.CrossRefGoogle ScholarPubMed
Giles, JT, Bathon, JM. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med. 2004; 19:320–34.CrossRefGoogle ScholarPubMed
Khanna, D, McMahon, M, Furst, . Safety of tumour necrosis factor-alpha antagonists. Drug Saf. 2004; 27:307–24.CrossRefGoogle ScholarPubMed
Scheinfeld, N.A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat. 2004; 15:280–94.CrossRefGoogle ScholarPubMed
Behnam, SM, Behnam, SE, Koo, JY. TNF-alpha inhibitors and congestive heart failure. Skinmed. 2005; 4:363–8.Google ScholarPubMed
Mousa, SA, Goncharuk, O, Miller, D. Recent advances of TNF-alpha antagonists in rheumatoid arthritis and chronic heart failure. Expert Opin Biol Ther. 2007; 7:617–25.CrossRefGoogle ScholarPubMed
Chung, ES, Packer, M, Lo, KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003; 107:3133–40.CrossRefGoogle ScholarPubMed
Kwon, HJ, Cote, TR, Cuffe, MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003; 138:807–11.CrossRefGoogle ScholarPubMed
Desai, SB, Furst, . DE Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006; 20:757–90.CrossRefGoogle ScholarPubMed
,TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1999; 53:457–65.CrossRef
Oosten, BW, Barkhof, F, Truyen, L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996; 47:1531–4.CrossRefGoogle ScholarPubMed
Furst, , Breedveld, FC, Kalden, JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis. 2005; 64 Suppl 4:iv2–14.CrossRefGoogle Scholar
Tom, WL, Miller, MD, Hurley, MY, et al. Efalizumab-induced autoimmune pancytopenia. Br J Dermatol. 2006; 155:1045–7.CrossRefGoogle ScholarPubMed
Scheinfeld, N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf. 2006; 5:197–209.CrossRefGoogle Scholar
Mohan, N, Edwards, ET, Cupps, TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004; 31:1955–8.Google ScholarPubMed
Saint, MB, Bandt, M.Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine. 2006; 73:710–3.Google Scholar
Tobon, GJ, Canas, C, Jaller, JJ, et al. Serious liver disease induced by infliximab. Clin Rheumatol. 2007; 26:578–81.CrossRefGoogle ScholarPubMed
Wahie, S, Alexandroff, A, Reynolds, NJ. Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis. Clin Exp Dermatol. 2006; 31:460–1.CrossRefGoogle ScholarPubMed
Roenigk, HH, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 1998; 38:478–85.CrossRefGoogle ScholarPubMed
Peckham, PE, Weinstein, GD, McCullough, JL. The treatment of severe psoriasis. A national survey. Arch Dermatol. 1987; 123:1303–7.CrossRefGoogle ScholarPubMed
Gutierrez-Urena, S, Molina, JF, Garcia, CO, et al. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 1996; 39:272–6.CrossRefGoogle ScholarPubMed
Lim, AY, Gaffney, K, Scott, DG. Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology (Oxford). 2005; 44:1051–5.CrossRefGoogle ScholarPubMed
Kuitunen, T, Malmstrom, J, Palva, E, Pettersson, T. Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register from 1991 to 1999. Scand J Rheumatol. 2005; 34:238–41.CrossRefGoogle ScholarPubMed
Imokawa, S, Colby, TV, Leslie, KO, Helmers, RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000; 15:373–81.CrossRefGoogle ScholarPubMed
Barrera, P, Laan, RF, van Riel, PL, et al. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis. 1994; 53:434–9.CrossRefGoogle ScholarPubMed
Searles, G, McKendry, RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol. 1987; 14:1164–71.Google Scholar
Cattaneo, D, Perico, N, Gaspari, F, Remuzzi, G. Nephrotoxic aspects of cyclosporine. Transplant Proc. 2004; 36:234S–239S.CrossRefGoogle ScholarPubMed
Jumani, A, Hala, K, Tahir, S, et al. Causes of acute thrombotic microangiopathy in patients receiving kidney transplantation. Exp Clin Transplant. 2004; 2:268–72.Google ScholarPubMed
Vercauteren, SB, Bosmans, JL, Elseviers, MM, et al. A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases. Kidney Int. 1998; 54:536–45.CrossRefGoogle ScholarPubMed
Calne, RY, Rolles, K, White, DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979; 2:1033–6.Google ScholarPubMed
Humphreys, TR, Leyden, JJ. Acute reversible central nervous system toxicity associated with low-dose oral cyclosporine therapy. J Am Acad Dermatol. 1993; 29:490–2.CrossRefGoogle ScholarPubMed
Porges, Y, Blumen, S, Fireman, Z, et al. Cyclosporine-induced optic neuropathy, ophthalmoplegia, and nystagmus in a patient with Crohn disease. Am J Ophthalmol. 1998; 126:607–9.CrossRefGoogle Scholar
Gijtenbeek, JM, Bent, MJ, Vecht, CJ. Cyclosporine neurotoxicity: a review. J Neurol. 1999; 246:339–46.CrossRefGoogle ScholarPubMed
Bechstein, WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int. 2000; 13:313–26.CrossRefGoogle ScholarPubMed
Serkova, NJ, Christians, U, Benet, LZ. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv. 2004; 4:97–107.CrossRefGoogle ScholarPubMed
Carleton, BC, Smith, MA, Gelin, MN, Heathcote, SC. Paediatric adverse drug reaction reporting: understanding and future directions. Can J Clin Pharmacol. 2007; 14:e45–e57.Google ScholarPubMed
Strahan, JE, Raimer, S. Isotretinoin and the controversy of psychiatric adverse effects. Int J Dermatol. 2006; 45:789–99.CrossRefGoogle ScholarPubMed
Strauss, JS, Krowchuk, DP, Leyden, JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007; 56:651–63.CrossRefGoogle ScholarPubMed
Goldsmith, , Bolognia, JL, Callen, JP, et al. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol. 2004; 50:900–6.CrossRefGoogle ScholarPubMed
Orion, E, Matz, H, Wolf, R. The life-threatening complications of dermatologic therapies. Clin Dermatol. 2005; 23:182–92.CrossRefGoogle ScholarPubMed
Friedman, DI. Medication-induced intracranial hypertension in dermatology. Am J Clin Dermatol. 2005; 6:29–37.CrossRefGoogle ScholarPubMed
Bigby, M, Stern, RS. Adverse reactions to isotretinoin. A report from the Adverse Drug Reaction Reporting System. J Am Acad Dermatol. 1988; 18:543–52.CrossRefGoogle ScholarPubMed
Fraunfelder, FT, Fraunfelder, FW, Edwards, R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol. 2001; 132:299–305.CrossRefGoogle ScholarPubMed
Passier, JL, Srivastava, N, Puijenbroek, EP. Isotretinoin-induced inflammatory bowel disease. Neth J Med. 2006; 64:52–4.Google ScholarPubMed
Greene, JP. An adolescent with abdominal pain taking isotretinoin for severe acne. South Med J. 2006; 99:992–4.CrossRefGoogle ScholarPubMed
Jamshidi, M, Obermeyer, RJ, Govindaraj, S, et al. Acute pancreatitis secondary to isotretinoin-induced hyperlipidemia. J Okla State Med Assoc. 2002; 95:79–80.Google ScholarPubMed
Gelfand, EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol. 2006; 6:592–9.CrossRefGoogle ScholarPubMed
Orbach, H, Tishler, M, Shoenfeld, Y. Intravenous immunoglobulin and the kidney – a two-edged sword. Semin Arthritis Rheum. 2004; 34:593–601.CrossRefGoogle ScholarPubMed
Hamrock, DJ.Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2006; 6:535–42.CrossRefGoogle ScholarPubMed
Epstein, JS, Zoon, KC. Important drug warning: immune globulin intravenous (human) (IGIV) products. Neonatal Netw. 2000; 19:60–2.Google ScholarPubMed
Caress, JB, Cartwright, MS, Donofrio, PD, Peacock, JE. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology. 2003; 60:1822–4.CrossRefGoogle ScholarPubMed
Marie, I, Maurey, G, Herve, F, Hellot, MF, Levesque, H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol. 2006; 155:714–21.CrossRefGoogle ScholarPubMed
Vo, AA, Cam, V, Toyoda, M, et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin J Am Soc Nephrol. 2006; 1:844–52.CrossRefGoogle ScholarPubMed
Moris, G, Garcia-Monco, JC. The challenge of drug-induced aseptic meningitis. Arch Intern Med. 1999; 159:1185–94.CrossRefGoogle ScholarPubMed
Sekul, EA, Cupler, EJ, Dalakas, MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994; 121:259–62.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×